Poly Medicure Limited (NSE:POLYMED) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

It's been a good week for Poly Medicure Limited (NSE:POLYMED) shareholders, because the company has just released its latest quarterly results, and the shares gained 9.6% to ₹2,487. Poly Medicure reported ₹4.2b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of ₹8.48 beat expectations, being 2.8% higher than what the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

See our latest analysis for Poly Medicure

Taking into account the latest results, the consensus forecast from Poly Medicure's six analysts is for revenues of ₹20.7b in 2026. This reflects a substantial 29% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 39% to ₹43.35. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹20.8b and earnings per share (EPS) of ₹43.32 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

The analysts reconfirmed their price target of ₹2,482, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Poly Medicure, with the most bullish analyst valuing it at ₹2,998 and the most bearish at ₹1,999 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Poly Medicure shareholders.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Poly Medicure's past performance and to peers in the same industry. The analysts are definitely expecting Poly Medicure's growth to accelerate, with the forecast 23% annualised growth to the end of 2026 ranking favourably alongside historical growth of 18% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 14% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Poly Medicure is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Poly Medicure going out to 2027, and you can see them free on our platform here..

You can also see our analysis of Poly Medicure's Board and CEO remuneration and experience, and whether company insiders have been buying stock.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.